NCT01030640 - Study To Assess Changes In The Number Of Nerves In The Skin At The Site Where Where Tanezumab Is Injected | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions

Osteoarthritis PainChronic Low Back PainPain Due to Interstitial Cystitis

Interventions

OTHER

placebo

single dose of the drug formulation

BIOLOGICAL

tanezumab

single dose of the active drug tanezumab at a dose level of 20 mg

Trial Locations (2)

Pfizer Investigational Site, Overland Park

Pfizer Investigational Site, Overland Park